CD4 and melanoma: After successfully stimulating an antitumor immune response against the GILT expressing melanoma, the patient's melanoma cells, not expressing GILT, could be recognized by both immune effector cells, CTLs and NK T cells, and immune regulating CD4+ T cells; further improving tumor regression.